Drug intelligence / Profile preview

FluShield

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**FluShield** was a Wyeth seasonal injectable **trivalent inactivated split-virion influenza vaccine** used for active immunization against influenza. The documented 1996-1997 formulation contained 15 micrograms of hemagglutinin from each of three strains: A/Texas/36/91 H1N1, A/Wuhan/359/95 H3N2, and B/Beijing/184/93. It induces strain-specific anti-influenza antibody responses against viral hemagglutinin antigens. Wyeth announced cessation of FluShield production in January 2003, before the 2003-2004 influenza season. ([infectioncontroltoday.com](https://www.infectioncontroltoday.com/view/wyeth-ceases-production-its-injectable-influenza-vaccine-and-pneumococcal))

Brand names: FluShield
Other names: Flushield

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on FluShield.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FluShield.

Explore the full profile